Benefits of Therapy With Virtual Reality Exposure in the Treatment of Cocaine Use Disorders

NCT ID: NCT04280900

Last Updated: 2020-02-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cocaine addiction is a multifactorial disease with important consequences: somatic, psychiatric... The number of applications for treatment for cocaine addiction is gradually increasing from year to year but no conventional treatment is available. New tools such as virtual reality could be used in this treatment. We propose to create a virtual reality program based on the analysis of high-risk relapse situations described by patients. We will then assess the effect of this cybertherapy on patients' relapse time and their desire to use cocaine

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In France, according to the Health Barometer 2017, cocaine testing has seen two decades of increases from 1.2% in 1995 to 5.6% in 2017, making it the second most widely used illicit substance. About 5% of cocaine users may become addicted in the first year of use, while 20% will develop long-term addiction. This dependence or substance use disorder is characterized in particular by a loss of control of cocaine use and continued use despite the negative consequences. Another of the central dimensions of this disorder is the craving (irresistible or irrepressible need or desire to consume) which is caused by internal or external stimuli. Craving is the cause of frequent loss of controls and re-consumption.

The treatment of cocaine addictions is generally based on a dual model of pharmacological treatment often aimed at limiting craving and psychotherapeutic treatment in order to alter the emotions and memory associated with cocaine use; for example: relearning product management when it comes to the subject.

In this context, the use of a 3D tool, which allows a gradual and well-detested exposure without confrontation, seems an interesting prospect. Virtual reality therapies have historically been known for treating phobias (fears). In addictions, exposure therapies are done in imagination and rarely with consumer-inducing situations. Since 2000, several researchers have successfully used virtual reality applications in addictions, but there is little data on objective assessments of the effectiveness of cybertherapy in the treatment of cocaine addictions.

All of these elements converge to propose a protocol called "CORVI" to evaluate the effectiveness of virtual reality exposure therapy as the management of patients with cocaine use disorder versus management classic.

The project is based on 3 phases: 1/construction of films that can be used in cybertherapy that reproduce situations in which there are stimuli generating "craving" to cocaine. 2/ Treatment of 2 randomized patient groups with and without cybertherapy (n-20/group) 3/Relapse evaluations at 1.2 and 3 months post-treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Addiction Cocaine-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cybertherapy

use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)

Group Type EXPERIMENTAL

Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)

Intervention Type BEHAVIORAL

use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)

Treatment as usual

Intervention Type BEHAVIORAL

Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)

Treatment as usual

Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)

Group Type OTHER

Treatment as usual

Intervention Type BEHAVIORAL

Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)

use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)

Intervention Type BEHAVIORAL

Treatment as usual

Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* suffering from a cocaine use disorder with craving criteria present according to the criteria of DSM 5
* wanting to stop cocaine use
* able to give informed consent to participate in research
* Covered by a Social Security plan.

Exclusion Criteria

Patient with:

* psychiatric comorbidities (DSM 5) unstabilized
* dipsomaniac alcoholism
* an anteriority of one or more hypomanic or manic episodes
* unstabilized psychosis
* an unstabilized depression
* a severe suicidal risk
* a syndrome of dependence on products other than cocaine or tobacco
* unstabilized anxiety
* problems that hinder participation in 3D exposure, as a tendency to dissociation; phobias of the type of information (panic attacks and hypochondria...) severe dizziness...
* cognitive problems limiting or preventing the possibility of implementing coping or managing emotions or stimuli and disabilities to complete questionnaires
* a language barrier
* a serious intercurrent pathology
* the need for weekly individual follow-up Patient in a protected population such as pregnant women, lactating women, patients under guardianship, guardianship, deprived of freedoms, or in safeguarding justice
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondation de l'Avenir, France

UNKNOWN

Sponsor Role collaborator

University Hospital, Clermont-Ferrand

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Georges Brousse

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Clermont-Ferrand

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Clermont Ferrand

Clermont-Ferrand, Auvergne, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lise Laclautre

Role: CONTACT

334.73.754.963

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lise Laclautre

Role: primary

0473754963

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-A02368-49

Identifier Type: OTHER

Identifier Source: secondary_id

RBHP 2019 BROUSSE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TDCS for Cocaine Addiction Craving
NCT03833583 COMPLETED NA